Recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(24 sites)

China

The Fifth Medical Center of the General Hospital of the People's Liberation Army of China, Beijing, Beijing Municipality

Fujian Cancer Hospital, Fuzhou, Fujian

Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital, Shenzhen, Guangdong

Guangxi Medical University Affiliated Cancer Hospital, Guilin, Guangxi

Harbin Medical University Affiliated Cancer Hospital, Ha’erbin, Heilongjjiang

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan

Henan Cancer Hospital, Zhengzhou, Henan

Hubei Cancer Hospital, Wuhan, Hubei

Xiangya Second Hospital of Central South University, Changsha, Hunan

Southeast University Affiliated Zhongda Hospital, Nanjing, Jiangsu

Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi

Affiliated Zhongshan Hospital Dalian University, Dalian, Liaoning

Dalian Medical University First Affiliated Hospital, Dalian, Liaoning

Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong

Jining First People's Hospital, Jining, Shandong

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Fudan University Affiliated Obstetrics and Gynecology Hospital, Shanghai, Shanghai Municipality

Shanxi Cancer Hospital, Taiyuan, Shanxi

The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi

Sichuan University West China Second Hospital, Chengdu, Sichuan

Yibin Second People's Hospital, Yibin, Sichuan

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality

Yun Cancer Hospital, Kunming, Yunnan

Zhejiang Cancer Hospital, Hangzhou, Zhejiang